More recently, Meininger et al. (2017) reported that treatment with Ozanezumab, a humanized monoclonal antibody against NogoA, showed no significant improvement for ALS patients in phase two trial, suggesting that NogoA may not be an effective therapeutic target. Here, RTN4 is linked to amyotrophic lateral sclerosis.